Tag: Hae

As the first preventive monoclonal antibody approved for hereditary angioedema (HAE), TAKHZYRO is a critical medication for managing the condition in patients as young as 2 years old. For many, this offers a life-changing alternative to older treatments with more complex administration schedules. This guide provides detailed instructions on **how to administer TAKHZYRO** correctly and safely, whether you are a patient or a caregiver.

Hereditary Angioedema (HAE) is a rare genetic disorder affecting about 1 in 50,000 people worldwide. For those living with this condition, understanding acute treatments is crucial. So, **what is the drug FIRAZYR used for?** It is an injectable medication for acute attacks of HAE in adults.